Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 2/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 9/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 3/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25933239 | 0.86 | ABL1 (0.54) | ABL1BCRPDPK1 | |
| SCHEMBL25936276 | 0.79 | GSK3B (0.37) | MAP2K4FGFR1GSK3BHDAC6CYP1A2 | |
| SCHEMBL25936342 | 0.76 | GSK3B (0.37) | MAP2K4FGFR1GSK3BCYP1A2PDPK1 | |
| SCHEMBL21656763 | 0.76 | GSK3B (0.44) | GSK3BPDPK1 | |
| SCHEMBL24137502 | 0.74 | JAK2 (0.48) | HDAC6PDPK1 | |
| SCHEMBL24137503 | 0.74 | MAP2K4 (0.55) | MAP2K4ABL1BCRPDPK1 | |
| SCHEMBL24137497 | 0.74 | MAP2K4 (0.54) | MAP2K4FGFR1HDAC6PDPK1 | |
| SCHEMBL25933236 | 0.74 | PDPK1 (0.49) | FGFR1ABL1BCRCYP1A2PDPK1 | |
| SCHEMBL14942621 | 0.73 | ITK (0.47) | MAP2K4GSK3BHDAC6 | |
| SCHEMBL24137787 | 0.73 | JAK2 (0.61) | FGFR1GSK3BPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | MAP2K4 97/4885FGFR1 600/4885GSK3B 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.